The effects of immune checkpoint inhibitors vs. chemotherapy combined with brain radiotherapy in non-small cell lung cancer patients with brain metastases

• Published in: BMC cancer 2024-10, Vol.24 (1), p.1343-15, Article 1343
• Main Authors: Wang, Tengfei, Li, Rumeng, Liu, Shuyan, Wu, Qiuji, Ouyang, Wen, Xie, Conghua
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Brain cancer; Brain metastasis; Brain Neoplasms - radiotherapy; Brain Neoplasms - secondary; Brain Neoplasms - therapy; Brain radiotherapy; Brain research; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - radiotherapy; Carcinoma, Non-Small-Cell Lung - therapy; Care and treatment; Chemoradiotherapy - methods; Chemotherapy; Chemotherapy, Combination; Clinical trials; Combination therapy; Combined Modality Therapy; Cranial Irradiation - methods; Dosage and administration; Female; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Magnetic resonance imaging; Male; Medical prognosis; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Mutation; Non-small cell lung cancer; Non-small cell lung carcinoma; Oncology; Patient outcomes; Patients; Prognosis; Quality of life; Radiation therapy; Radiosurgery; Radiotherapy; Retrospective Studies; Small cell lung carcinoma; Squamous cell carcinoma; Tomography
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-13110-y

Non-small cell lung cancer (NSCLC) is a prevalent form of cancer, often leading to brain metastases (BM) and a significant decline in patient prognosis. Whether immune checkpoint inhibitors (ICIs) combined with brain radiotherapy is superior to conventional chemotherapy combined with brain radiotherapy in those patients remains to be explored. Our study enrolled 161 NSCLC patients with BM who underwent either ICIs combined with brain radiotherapy or chemotherapy combined with brain radiotherapy. End points included overall survival (OS), progression-free survival (PFS), intracranial PFS (IPFS), and extracranial PFS (EPFS). Univariate and multivariate Cox regressions were employed to identify prognostic risk variables. Patients receiving ICIs combined with brain radiotherapy exhibited significantly longer OS compared to those receiving chemotherapy combined with brain radiotherapy (34.80 months vs. 17.17 months, P = 0.005). In the Cox regression analysis, chemotherapy combined with brain radiotherapy (HR, 1.82; 95% CI, 1.09-3.05; P = 0.023), smoking (HR, 1.75; 95% CI, 1.02-2.99; P = 0.043) and squamous cell carcinoma (HR, 2.59; 95% CI, 1.31-5.13; P = 0.006) were associated with a worse prognosis. After propensity score matching (PSM), this finding remained consistent with before PSM (43.73 months vs. 17.17 months, P = 0.018). Squamous cell carcinoma (HR, 2.46; 95% CI, 1.15-5.26; P = 0.021) and CT + RT (HR, 2.11; 95% CI, 1.15-3.88; P = 0.016) were associated with a less favorable prognosis. The study suggests that the combination of ICIs and brain radiotherapy provides superior OS for NSCLC patients with BM, compared to the chemotherapy combined with brain radiotherapy.